WORCESTER, Mass., March 11, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will hold a conference call on Friday, March 13, 2009 at 11:00 a.m. Eastern Time to update the investment community on the positive results following review of Phase III data for the Company’s flagship product, Generex Oral-lyn(tm); activity in the regions where the Company’s products have been approved for sale; progress on distribution of the Company’s over the counter products; and other corporate activities.
